Product Transference Study of Testagen™ TDS®-Testosterone
Status:
Enrolling by invitation
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of
Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has
been applied and the potential of product to raise serum androgen levels in those women.